Biogen isn’t shy about aspirations to expand beyond neurology and further establish itself in immunology and rare diseases. Recent business development deals have focused on enhancing the company’s ...
Hosted on MSN
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated ...
UCB SA (OTC:UCBJY) (OTC:UCBJF) (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) on Thursday presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Cambridge-based company's ...
Investors with a lot of money to spend have taken a bullish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the trades showed up on publicly available ...
Biogen beat Q2 2025 revenue and EPS estimates, but core MS and SPINRAZA franchises continue to erode, offset only partially by new products. Launches like ZURZUVAE and LEQEMBI show promise, yet their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results